Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose

BioMetals

Volumn 28, Issue 4, 2015, Pages 615-635

  Neiser, Susann ^a   Rentsch, Daniel ^b   Dippon, Urs ^c   Kappler, Andreas ^c   Weidler, Peter G ^d   Göttlicher, Jörg ^d   Steininger, Ralph ^d   Wilhelm, Maria ^a   Braitsch, Michaela ^a   Funk, Felix ^a   Philipp, Erik ^a   Burckhardt, Susanna ^a  

^a Preclinical Research   (Switzerland)

^b SWISS FEDERAL LABORATORIES FOR MATERIALS SCIENCE AND TECHNOLOGY   (Switzerland)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

Ferric carboxymaltose; Ferumoxytol; Intravenous iron; Iron isomaltoside 1000; Iron sucrose; Low molecular weight iron dextran

Indexed keywords

CARBOHYDRATE; DEXTRAN; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC OXIDE; FERUMOXYTOL; IRON; IRON DERIVATIVE; IRON DEXTRAN; IRON ISOMALTOSIDE 1000; IRON SACCHARATE; UNCLASSIFIED DRUG; DISACCHARIDE; FERRIC ION; MAGNETITE; MALTOSE;

ANALYTIC METHOD; ARTICLE; CARBOHYDRATE ANALYSIS; CARBOXYLATION; COMPARATIVE STUDY; COMPLEX FORMATION; DEGRADATION; DEGRADATION KINETICS; METHYLATION; MOLECULAR WEIGHT; MOSSBAUER SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; POLAROGRAPHY; QUALITATIVE ANALYSIS; SAFETY; X RAY ABSORPTION SPECTROSCOPY; X RAY DIFFRACTION; ANALOGS AND DERIVATIVES; CHEMISTRY; SYNTHESIS;

CHEMISTRY, PHYSICAL; DISACCHARIDES; FERRIC COMPOUNDS; FERROSOFERRIC OXIDE; IRON COMPOUNDS; MALTOSE; X-RAY DIFFRACTION;

EID: 84933277981     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-015-9845-9     Document Type: Article

References (71)

1. AMAG Pharmaceuticals Inc., Waltham, USA (2009) Feraheme prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/022180lbl.pdf. Accessed 19 July 2013
2. Andreasen HB, Christensen L (2001) Iron-dextran compound for the use as component in a therapeutical composition for prophylaxis or treatment of iron-deficiency. Patent US 6291,440
3. Auerbach M, Ballard H (2010) Clinical use of intravenous iron: administration, efficacy, and safety. Hematol Am Soc Hematol Educ Progr 2010:338-347
4. Avni T, Leibovici L, Gafter-Gvili A (2012) Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail 14:423-429
5. Balakrishnan VS, Rao M, Kausz AT, Brenner L, Pereira BJ, Frigo TB, Lewis JM (2009) Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 39:489-496
6. Barrero C, Garcia K, Morales A, Kodjikian S, Greneche J (2006) New analysis of the Mössbauer spectra of akaganeite. J Phys 18:6827-6840
7. Besarab A, Coyne DW (2010) Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 6:699-710
8. Bigham JM, Schwertmann U, Carlson L, Murad E (1990) A poorly crystallized oxyhydroxysulfate of iron formed by bacterial oxidation of Fe(II) in acid-mine waters. Geochim Cosmochim Acta 54:2743-2758
9. Borchard G, Flühmann B, Mühlebach S (2012) Nanoparticle iron medicinal products: requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Regul Toxicol Pharmacol 64:324-328
10. Breymann C, Honegger C, Holzgreve W, Surbek D (2010) Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet 282:577-580
11. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J (2006) Update on adverse drug events associated with parenteral iron. Nephrol Dial Transpl 21:378-382
12. Cornell RM, Schwertmann U (2003) The iron oxides; structure, properties, reactions, occurrences, and uses. Wiley-VCH, Weinheim
13. Coyne DW (2009) Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease. Expert Opin Pharmacother 10:2563-2568
14. Crichton R (2009) Iron metabolism from molecular mechanisms to clinical consequences. Wiley, Chichester
15. Crichton RR, Danielson BG, Geisser P (2008) Iron therapy with special emphasis on intravenous administration. UNI-MED, Bremen
16. Crommelin DJ, de Vlieger JS, Weinstein V, Mühlebach S, Shah VP, Schellekens H (2014) Different pharmaceutical products need similar terminology. AAPS J 16:11-14
17. Erni I, Oswald N, Rich HW, Schneider W (1984) Chemical characterization of iron (III)-hydroxide-dextrin complexes. A comparative study of commercial preparations with alleged reproductions used in the examination of bioavailability. Arzneimittelforschung 34:1555-1559
18. European Medicines Agency (2012) CHMP Assessment Report Rienso; Common name: ferumoxytol; Procedure No.: EMEA/H/C/002215. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/002215/WC500129751.pdf. Accessed 26 Mar 2013
19. Funk F, Long FG, Hautot D, Büchi R, Christl I, Weidler PG (2001) Physical and chemical characterization of therapeutic iron containing materials: a study of several superparamagnetic drug formulations with the beta-FeOOH or ferrihydrite structure. Hyperfine Interact 136:73-95
20. Fütterer S, Andrusenko I, Kolb U, Hofmeister W, Langguth P (2013) Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal 86C:151-160
21. Gafter-Gvili A, Rozen-Zvi B, Vidal L, Leibovici L, Vansteenkiste J, Gafter U, Shpilberg O (2013) Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol 52:18-29
22. Geisser P, Burckhardt S (2011) The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 3:12-33
23. Geisser P, Baer M, Schaub E (1992) Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 42:1439-1452
24. Gomollon F, Gisbert JP (2013) Intravenous iron in inflammatory bowel diseases. Curr Opin Gastroenterol 29:201-207
25. Goodnough LT, Nemeth E, Ganz T (2010) Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116:4754-4761
26. Groman, EV, Paul, KG, Frigo, TB, Bengele, H, Lewis, JM (2003) Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohydrate derivatives. Patent US 6,599,498
27. Haththotuwa R, Goonewardene M, Desai S, Senanayake L, Tank J, Fraser IS (2011) Management of abnormal uterine bleeding in low- and high-resource settings: consideration of cultural issues. Semin Reprod Med 29:446-458
28. Jahn MR, Mrestani Y, Langguth P, Neubert RH (2007) CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off-capillary and on-capillary complexation with EDTA. Electrophoresis 28:2424-2429
29. Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, Hofmeister W, Munoz M, Bock K, Meldal M, Langguth P (2011) A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 78:480-491
30. Jander G, Jahr KF, Schulze G, Simon J (2003) Massanalyse. Walter de Gruyter, Berlin
31. Kästele X, Sturm C, Klüfers P (2014) 13C NMR spectroscopy as a tool for the in situ characterisation of iron-supplementing preparations. Eur J Pharm Biopharm 86:469-477
32. Medice Pharma GmbH&Co. KG, Iserlohn, Germany (2011) MonoFer 100 mg/mL Lösung zur Injektion und Infusion. http://www.medice.de/produkte/nierenheilkunde/monoferae. Accessed 19 July 2013
33. Klug HP, Alexander LE (1974) X-ray diffraction procedures. Wiley, New York
34. Koskenkorva-Frank TS, Weiss G, Koppenol WH, Burckhardt S (2013) The complex interplay of iron metabolism, reactive oxygen and reactive nitrogen species: insights into the potential of different iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med 65:1174-1194
35. Kudasheva S, Lai J, Ulman A, Cowman MK (2004) Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Chem 98:1757-1769
36. Lippard SJ, Berg JM (1994) Principles of bioinorganic chemistry. University Science Books, Mill Valley
37. Macdougall IC, Geisser P (2013) Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis 7:9-22
38. Macdougall IC, Canaud B, de Francisco AL, Filippatos G, Ponikowski P, Silverberg D, van Veldhuisen DJ, Anker SD (2012) Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail 14:882-886
39. Mahmoudi L, Kissner R (2014) Electrode reactions of iron oxide-hydroxide colloids. Dalton Trans 43:15407-15413
40. Merli D, Profumo A, Dossi C (2012) An analytical method for Fe(II) and Fe(III) determination in pharmaceutical grade iron sucrose complex and sodium ferric gluconate complex. J Pharm Anal 2:450-453
41. Morup S, Tronc E (1994) Superparamagnetic relaxation of weakly interacting particles. Phys Rev Lett 72:3278-3281
42. Munoz M, Martin-Montanez E (2012) Ferric carboxymaltose for the treatment of iron-deficiency anemia. Expert Opin Pharmacother 13:907-921 (corrected)
43. Murad E (1996) Magnetic properties of microcrystalline iron(III) oxides and related materials as reflected in their Mossbauer spectra. Phys Chem Miner 23:248-262
44. Murad E, Cashion J (2004) Mössbauer spectroscopy of environmental materials and their industrial utilization. Kluwer Academic Publishers, Boston
45. Nordfjeld K, Andreasen H, Thomsen LL (2012) Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des Devel Ther 6:43-51
46. Pai AB, Garba AO (2012) Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med 3:77-85
47. Pawley GS (1981) Unit-cell refinement form powder diffraction scans. J Appl Cryst 14:357-361
48. 3, from reflectance measurement on pressed powders. Phys Chem Miner 22:21-29
49. Pharmacosmos A/S, Holbaek, Denmark (2009) Public Assessment Report, Scientific discussion, MonoFer(R) 100 mg/mL solution for injection/infusion (iron(III)isomaltoside 1000).SE/H/734/01/DC, 2009. http://www.lakemedelsverket.se/SPC-PIL/Pdf/par/Monofer%20solution%20for%20infusion-injection.pdf. Accessed 22 March 2013
50. Post JE, Buchwald VF (1991) Crystal structure refinement of akaganeite. Am Miner 76:272-277
51. Qunibi WY (2010) The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 60:399-412
52. Ravel B, Newville M (2005) ATHENA, ARTEMIS, HEPHAESTUS: data analysis for X-ray absorption spectroscopy using IFEFFIT. J Synchrotron Radiat 12:537-541
53. Rosner MH, Auerbach M (2011) Ferumoxytol for the treatment of iron deficiency. Expert Rev Hematol 4:399-406
54. Schellekens H, Stegemann S, Weinstein V, de Vlieger JS, Flühmann B, Mühlebach S, Gaspar R, Shah VP, Crommelin DJ (2014) How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. AAPS J 16:15-21
55. Shander A, Van AH, Colomina MJ, Gombotz H, Hofmann A, Krauspe R, Lasocki S, Richards T, Slappendel R, Spahn DR (2012) Patient blood management in Europe. Br J Anaesth 109:55-68
56. Simon GH, von Vopelius-Feldt J, Fu Y, Schlegel J, Pinotek G, Wendland MF, Chen MH, Daldrup-Link HE (2006) Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol. Invest Radiol 41:45-51
57. Steen DL, Cannon CP, Lele SS, Rajapurkar MM, Mukhopadhyay B, Scirica BM, Murphy SA, Morrow DA (2013) Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clin Cardiol 36:139-145
58. Stefansson BV, Haraldsson B, Nilsson U (2011) Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. Nephron Clin Pract 118:c249-c256
59. Toblli JE, Cao G, Oliveri L, Angerosa M (2012) Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm Allergy Drug Targets 11:66-78
60. 3 nanoparticles. J Magn Magn Mater 221:63-79
61. Tucek J, Zboril R, Petridis D (2006) Maghemite nanoparticles by view of Mössbauer spectroscopy. J Nanosci Nanotechnol 6:926-947
62. U.S. Food and Drug Administration (2012a) Draft guidance on iron sucrose. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM297630.pdf. Accessed 19 July 2013a
63. U.S. Food and Drug Administration (2012b) Iron sucrose injection, official monograph. United States Pharmacopeial Convention, Rockville, pp 3564-3566
64. U.S. Food and Drug Administration (2013) Draft guidance on sodium ferric gluconate complex. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358142.pdf. Accessed 19 July 2013
65. Van Wyck DB (2004) Labile iron: manifestations and clinical implications. J Am Soc Nephrol 15(Suppl 2):S107-S111
66. Van Wyck DB, Anderson J, Johnson K (2004) Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transpl 19:561-565
67. von Drygalski A, Adamson JW (2012) Iron metabolism in man. JPEN 37(5):599-606
68. von Haehling S, Anker MS, Jankowska EA, Ponikowski P, Anker SD (2012) Anemia in chronic heart failure: can we treat? What to treat? Heart Fail Rev 17:203-210
69. Woodcock J (2011) FDA/CDER to Chesapeake Regulatory Group, Inc., Frommer Lawrence and Haug LLP, and Covington & Burling LLP: Petition Partial Approval and Denial. http://www.regulations.gov/#!documentDetail;D=FDA-2004-P-0494-0008. Accessed 2 July 2013
70. Young, RA (1993) Introduction to the Rietveld method. In:Young, RA (ed) The Rietveld Method, Oxford University Press, Oxford, pp IUCr book series
71. Zager RA, Johnson AC, Hanson SY (2004) Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 65:2108-2112